Evaluation of the Acceptability and Therapeutic Maintenance After Substitution of Ustekinumab With a Biosimilar

RecruitingOBSERVATIONAL
Enrollment

246

Participants

Timeline

Start Date

June 2, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

December 31, 2027

Conditions
Crohn Disease (CD)
Trial Locations (11)

25000

NOT_YET_RECRUITING

Chu Besançon - Hopital Jean Minjoz, Besançon

34295

RECRUITING

Chu Montpellier - Hopital Saint Eloi, Montpellier

44093

RECRUITING

Chu Nantes, Nantes

54500

RECRUITING

Chu Nancy Brabois, Vandœuvre-lès-Nancy

64109

RECRUITING

Chu de La Côte Basque, Bayonne

76000

RECRUITING

CHU Rouen Normandie, Rouen

80090

RECRUITING

Cabinet Medical, Amiens

92200

RECRUITING

Institut Des Mici Groupe Hospitalier, Neuilly-sur-Seine

Unknown

RECRUITING

Chu La Cavale Blanche, Brest

RECRUITING

Clinique Jules Verne, Nantes

RECRUITING

Chu Lyon Sud, Pierre-Bénite

Sponsors

Lead Sponsor

All Listed Sponsors
lead

EG Labo

INDUSTRY